Benefits of PARP Inhibitor Use in Breast Cancer

Video

Jennifer Litton, MD, Breast Medical Oncologist, MD Anderson Cancer Center, describes how PARP inhibitors compare to standard of care in breast cancer treatment.

Recent Videos
Photo of a woman with brown hair and bangs, surrounded by a blue border
5 experts in this video
Related Content
Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

Ashley Chan
March 25th 2025
Article
Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Illustration of small patient and provider characters surrounded by larger technology devices with medical information coming off of the screens and other medical props nearby

Mobile App May Be Feasible for Tracking Oral Cancer Medication Adherence

Bridget Hoyt
March 10th 2025
Article

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Blue rendering of a person with breast tissue highlighted in orange

T-DM1 Further Improves DFS and OS vs Trastuzumab in HER2-Positive Early Breast Cancer

Bridget Hoyt
February 20th 2025
Article

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

Blue image of a breast with tissue and a tumor highlighted in orange

KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

Ashling Wahner
February 17th 2025
Article

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.